Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies

v3.22.2
Commitments and Contingencies
6 Months Ended
Jun. 30, 2022
Commitments and Contingencies  
Note 8 - Commitments And Contingencies

Note 8 – Commitments and Contingencies

 

a) Finance Lease Obligations

 

In 2016, the Company entered into a capital lease with ING Asset Finance Belgium S.A. (“ING”) to purchase a property located in Belgium for €1.12 million, maturing in May 2031 with implicit interest of 2.62%. As of June 30, 2022, the balance payable was $492,173.

 

In 2018, the Company entered into a capital lease with BNP Paribas leasing solutions to purchase a freezer for the Belgium facility for €25,000, that matured in January 2022 with implicit interest of 1.35%. The leased equipment is amortized on a straight-line basis over 5 years. As of June 30, 2022, the balance payable was $nil.

 

The following is a schedule showing the future minimum lease payments under finance leases by years and the present value of the minimum payments as of June 30, 2022.

 

2022 - remaining

 

$ 28,145

 

2023

 

$ 56,292

 

2024

 

$ 56,291

 

2025

 

$ 56,291

 

2026

 

$ 56,292

 

Greater than 5 years

 

$ 302,554

 

Total

 

$ 555,865

 

Less: Amount representing interest

 

$ (63,692 )

Present value of minimum lease payments

 

$ 492,173

 

 

b) Operating Lease Right-of-Use Obligations

 

As all the existing leases subject to the new lease standard ASC 842 (“Leases”) were previously classified as operating leases by the Company, they were similarly classified as operating leases under the new standard. The Company has determined that the identified operating leases did not contain non-lease components and require no further allocation of the total lease cost. Additionally, the agreements in place did not contain information to determine the rate implicit in the leases, so the Company used its incremental borrowing rate as the discount rate. The Company’s weighted average discount rate is 2.43% and the weighted average remaining lease term is 31 months.

 

During the six months ended June 30, 2022, the Company entered into a new lease agreement. The lease is initially for 62 months and the initial rent is $7,642 a month. In connection with the new lease agreement the Company recorded $461,341 of right of use assets in exchange for right of use liabilities.

 

As of June 30, 2022, operating lease right-of-use assets and liabilities arising from operating leases were $739,015 and $761,323, respectively. During the six months ended June 30, 2022, cash paid for amounts included for the measurement of lease liabilities was $102,424 and the Company recorded operating lease expense of $120,733.

 

The following is a schedule showing the future minimum lease payments under operating leases by years and the present value of the minimum payments as of June 30, 2022.

 

2022 - remaining

 

$ 127,652

 

2023

 

$ 263,097

 

2024

 

$ 162,756

 

2025

 

$ 119,712

 

2026

 

$ 120,400

 

Total Operating Lease Obligations

 

$ 793,617

 

Less: Amount representing interest

 

$ (32,294 )

Present Value of minimum lease payments

 

$ 761,323

 

 

The Company’s office space leases are short-term and the Company has elected under the short-term recognition exemption not to recognize them on the balance sheet. During the six months ended June 30, 2022, the Company recognized $41,708 in short-term lease costs associated with office space leases. The annual payments remaining for short-term office leases were as follows:

 

2022 - remaining

 

$ 25,715

 

2023

 

$ 22,505

 

Total Operating Lease Liabilities

 

$ 48,220

 

 

c) Grants Repayable

 

In 2010, the Company entered into an agreement with the Walloon Region government in Belgium for a colorectal cancer research grant for €1.05 million. Per the terms of the agreement, €314,406 of the grant is to be repaid, by installments over the period from June 30, 2014 to June 30, 2023. In the event that the Company receives revenue from products or services as defined in the agreement, it is due to pay a 6% royalty on such revenue to the Walloon Region. The maximum amount payable to the Walloon Region, in respect of the aggregate of the amount repayable of €314,406 and the 6.00% royalty on revenue, is equal to twice the amount of funding received. As of June 30, 2022, the grant balance repayable was $57,562.

 

In 2018, the Company entered into an agreement with the Walloon Region government in Belgium for a colorectal cancer research grant for €605,000. Per the terms of the agreement, €181,500 of the grant is to be repaid by installments over 12 years commencing in 2020. In the event that the Company receives revenue from products or services as defined in the agreement, it is due to pay a 3.53% royalty on such revenue to the Walloon Region. The maximum amount payable to the Walloon Region, in respect of the aggregate of the amount repayable of €181,500 and the 3.53% royalty on revenue, is equal to the amount of funding received. As of June 30, 2022, the grant balance repayable was $112,340.

 

In 2020, the Company entered into an agreement with the Walloon Region government in Belgium for a research grant for €929,433. Per the terms of the agreement, €278,830 of the grant is to be repaid by installments over 15 years commencing in 2022. In the event that the Company receives revenue from products or services as defined in the agreement, it is due to pay a 4.34% royalty on such revenue to the Walloon Region. The maximum amount payable to the Walloon Region, in respect of the aggregate of the amount repayable of €278,830 and the 4.34% royalty on revenue, is equal to the amount of funding received. As of June 30, 2022, the grant balance repayable was $48,605.

 

In 2020, the Company entered into an agreement with the Walloon Region government in Belgium for a research grant for €495,000. Per the terms of the agreement, €148,500 of the grant is to be repaid by installments over 10 years commencing in 2023. In the event that the Company receives revenue from products or services as defined in the agreement, it is due to pay a 2.89% royalty on such revenue to the Walloon Region. The maximum amount payable to the Walloon Region, in respect of the aggregate of the amount repayable of €148,500 and the 2.89% royalty on revenue, is equal to the amount of funding received. As of June 30, 2022, the grant balance repayable was $54,092.

 

As of June 30, 2022, the total grant balance repayable was $272,599 and the payments remaining were as follows:

 

2022 - remaining

 

$ 40,743

 

2023

 

$ 39,179

 

2024

 

$ 17,002

 

2025

 

$ 18,716

 

2026

 

$ 24,600

 

Greater than 5 years

 

$ 132,359

 

Total Grants Repayable

 

$ 272,599

 

 

d) Long-Term Debt

 

In 2016, the Company entered into a 7-year loan agreement with Namur Invest for €440,000 with a fixed interest rate of 4.85%, maturing in December 2023. As of June 30, 2022, the principal balance payable was $119,470.

 

In 2016, the Company entered into a 15-year loan agreement with ING for €270,000 with a fixed interest rate of 2.62%, maturing in December 2031. As of June 30, 2022, the principal balance payable was $192,996.

 

In 2017, the Company entered into a 7-year loan agreement with SOFINEX for up to €1 million with a fixed interest rate of 4.50%, maturing in September 2024. As of June 30, 2022, €1 million had been drawn down under this agreement and the principal balance payable was $575,615.

 

In 2018, the Company entered into a 4-year loan agreement with Namur Innovation and Growth for €500,000 with a fixed interest rate of 4.00%, maturing in June 2022. As of June 30, 2022, the principal balance payable was $0.

 

In 2019, the Company entered into a 4-year loan agreement with Namur Innovation and Growth for €500,000 with a fixed interest rate of 4.80%, maturing in September 2024. As of June 30, 2022, the principal balance payable was $346,385.

 

On October 13, 2020, the Company entered into a 10-year loan agreement with Namur Invest for a maximum of €830,000 with fixed interest rate of 4.00%, maturing March 2031. As of June 30, 2022, the principal balance payable was $778,072.

 

On November 23, 2021, the Company entered into a 3 ½ year loan agreement with SOFINEX for a maximum of €450,000 with fixed interest rate of 5.00%, maturing June 2025. As of June 30, 2022, the principal balance payable was $470,958.

 

On February 5, 2022, the Company entered into a 9-month loan agreement with First Insurance Funding for a maximum of $620,549 with fixed interest rate of 3.57%, maturing November 2022. As of June 30, 2022, the maximum has been drawn down under this agreement and the principal balance payable was $344,749.

 

As of June 30, 2022, the total balance for long-term debt payable was $2,828,245 and the payments remaining were as follows:

 

2022 - remaining

 

$ 796,290

 

2023

 

$ 772,436

 

2024

 

$ 631,800

 

2025

 

$ 208,663

 

2026

 

$ 128,713

 

Greater than 5 years

 

$ 564,414

 

Total

 

$ 3,102,316

 

Less: Amount representing interest

 

$ (274,071 )

Total Long-Term Debt

 

$ 2,828,245

 

 

e) Collaborative Agreement Obligations

 

In 2016, the Company entered into a research co-operation agreement with DKFZ in Germany for a five-year period for €400,000. As of June 30, 2022, $209,315 is still to be paid by the Company under this agreement.

 

In 2018, the Company entered into a research collaboration agreement with the University of Taiwan for a three-year period for a cost to the Company of up to $2.55 million payable over such period. As of June 30, 2022, $510,000 is still to be paid by the Company under this agreement.

 

In 2019, the Company entered into a funded sponsored research agreement with the Texas A&M University (“TAMU”) in consideration for the license granted to the Company for a five-year period for a cost to the Company of up to $400,000 payable over such period. As of June 30, 2022, $18,994 is still to be paid by the Company under this agreement.

 

On September 16, 2020, the Company entered into a research agreement for the bioinformatic analysis of cell-free DNA fragments from whole-genome sequencing with the Hebrew University of Jerusalem for six months for a cost to the Company of €54,879. Subsequently the parties entered into an amendment to the agreement with an additional cost to the Company of €100,236. In the three months ended June 30, 2022, the parties entered into agreements for an additional cost to the Company of €39,000. As of June 30, 2022, $46,170 is still to be paid by the Company under the amended agreement.

 

As of June 30, 2022, the total amount to be paid for future research and collaboration commitments was approximately $ 784,479 and the payments remaining were as follows:

 

2022 - remaining

 

$ 784,479

 

2022 - 2026

 

$ -

 

Total Collaborative Agreement Obligations

 

$ 784,479

 

f) Other Commitments

 

Volition Vet

 

On October 25, 2019, the Company entered into an agreement with TAMU for provision of in kind services of personnel, animal samples and laboratory equipment in exchange for a non-controlling interest of 7.5% in Volition Vet with an additional 5%, vesting in a year from the date of the agreement, giving TAMU in aggregate, a 12.5% equity interest as of such date. As of June 30, 2022, TAMU has a 12.5% equity interest in Volition Vet.

 

Volition Germany

 

On January 10, 2020, the Company, through its wholly-owned subsidiary Belgian Volition, acquired an epigenetic reagent company, Octamer GmbH (“Octamer”), based in Munich, Germany, and hired its founder for his expertise and knowledge to be passed to Company personnel. On March 9, 2020, Octamer was renamed to Volition Germany GmbH (or “Volition Germany”).

 

In connection with the transaction agreement, the Company entered into a royalty agreement with the founder providing for the payment of royalties in the amount of 6% of net sales of Volition Germany’s nucleosomes as reagents to pharmaceutical companies for use in the development, manufacture and screening of molecules for use as therapeutic drugs for a period of five years post-closing.

 

As of June 30, 2022, $217 is payable under the 6% royalty agreement on sales to date towards the Company’s aggregate minimum royalty obligation of $134,217.

 

Volition America

 

On November 3, 2020, the Company entered into a professional services master agreement with Diagnostic Oncology CRO, LLC ("DXOCRO") to conduct a pivotal clinical trial and provide regulatory submission and reimbursement related services. Under the terms of the agreement DXOCRO will provide ad hoc consulting assistance on a project-by-project basis related to the review and assessment of existing data and information to prepare recommended intended use claims and coverage/reimbursement plans to support the preparation of FDA pre-submissions, clinical trial protocol development and study administration, and potential 510k regulatory marketing submissions of the Company’s diagnostic tests, including those proposed for use as an adjunct diagnostic tool for common and aggressive forms of non-Hodgkin’s lymphoma. The initial projects contemplated by the agreement relating to non-Hodgkin’s lymphoma obligate the Company to pay in aggregate of up to $2.9 million over a period of 22 months. Such payment obligations are on a project-by-project basis as deliverables are executed and subject to certain terms and conditions. Additionally, the Company may terminate the agreement or any project with or without cause upon at least 30 days’ prior written notice. Unless earlier terminated, the term of the agreement is until December 31, 2025 or such later date as when all projects have been completed. As of June 30, 2022, $4,375 is payable by Company for services rendered under the agreement.

 

g) Legal Proceedings

 

There are no legal proceedings which the Company believes will have a material adverse effect on its financial position.

 

h) Commitments in Respect of Corporate Goals and Performance-Based Awards

 

In August 2021 and October 2021 the Compensation Committee of the Board of Directors approved the granting of equity-based awards under the 2015 Stock Incentive Plan as well as cash bonuses, vesting upon achievement of certain corporate goals focused around product development and commercialization, to various personnel including directors, executives, members of management, consultants and employees of the Company and/or its subsidiaries.

 

Conditional upon the achievement by July 1, 2022 of all specified corporate goals as set forth in the minutes of the Compensation Committee, as well as continued service by the award recipient, the Company at the sole discretion of the Chief Executive Officer and the Chief Financial Officer would pay a cash bonus to such award recipient. As of June 30, 2022, the Company has accrued compensation expense of $737,137 based on the actual outcomes related to the prescribed performance targets.

 

As discussed in detail in Note 8, - Stock-Based Compensation, of the notes to consolidated financial statements contained in the Annual Report on Form 10-K for the year ended December 31, 2021, an aggregate of 1,000,000 stock options and 500,000 RSUs were issued under the 2015 Stock Incentive Plan in connection with the August and October 2021 grants.

 

On June 23, 2022, the Compensation Committee of the Board of Directors approved the achievement of all of the remaining outstanding corporate goals resulting in the payment of the cash bonus awards and the vesting of the rights to the equity-based awards, which equity-based awards remain subject to time-based vesting in equal installments on each of August 3, 2022 and August 3, 2023 (with the exception of October 4, 2022 and October 4, 2023 for one award) and the continuous service of the award recipient through the applicable vesting date.

 

As of June 30, 2022, the Company has recognized compensation expense of $1,303,627 in relation to such stock options and $1,113,059 in relation to such RSUs, based on the probable outcomes related to the prescribed performance targets on the outstanding awards.

 

As of June 30, 2022, the Company has unrecognized compensation expense of $635,526 in relation to such stock options and $541,337 in relation to such RSUs, based on the probable outcomes related to the prescribed performance targets on the outstanding awards.